EGFR and neoplasm: In the ADAURA study, osimertinib, a third-generation tyrosine kinase inhibitor that was administered as an adjuvant in EGFR mutated NSCLC, was associated with an 80% reduction of recurrence compared to placebo after surgical resection of the tumor.